EMERGENT BIOSOLUTIONS INC. COMMON STOCK

NetDania - New 12 months High: EMERGENT BIOSOLUTIONS INC. COMMON STOCK

02 Jul 2024 11:02:06 By NetDania Notify

Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

02 Jul 2024 08:43:07 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

02 Jul 2024 07:13:43 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

20 Jun 2024 06:00:57 By Nasdaq GlobeNewswire

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day

06 Jun 2024 08:02:45 By Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

10 May 2024 06:17:11 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports First Quarter 2024 Financial Results

01 May 2024 15:57:22 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

01 May 2024 15:10:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

01 May 2024 10:03:28 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

30 Apr 2024 16:26:55 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

22 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

28 Mar 2024 07:15:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

25 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

06 Mar 2024 15:31:01 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

29 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

21 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 Nov 2023 05:59:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 Nov 2023 06:30:00 By Nasdaq GlobeNewswire